Medical assistance in dying (MAID), often known as voluntary euthanasia, accounted for 4.7% of Canadian deaths in 2023, according to new Health Canada data.

According to Heath Canada’s fifth annual report, since the Trudeau government legalized MAID in 2016, about 15,300 persons will undergo assisted death in 2023 if their applications are granted.

The median age in this group was more than 77. The great majority, almost 96%, died from “reasonably foreseeable” causes, such as cancer.

In a tiny number of other cases, patients may not have been terminally sick but wanted assisted suicide owing to a protracted and difficult illness that had significantly reduced their quality of life.

Canada is one of a few countries that have passed assisted dying legislation in the last decade. Others include Australia, New Zealand, Spain, and Austria.

In Canada, consenting adults can request medical help in dying from a healthcare physician if they have a serious and irreversible medical condition. Some constraints exist, such as requiring two independent healthcare providers to certify the patient’s eligibility before the request is authorized.

Quebec Highest in MAID Deaths

In 2023, more than 320,000 individuals died in Canada, with medical assistance accounting for 15,300 of those fatalities (or around one in every 20).

According to estimates presented by Health Canada on Wednesday, the rate of assisted dying in Canada would rise by about 16% in 2023. This figure represents a significant decrease from the average increase of 31% in prior years.

The research stated that it is too early to determine what caused the rate to slow. For the first time, the report examined race and ethnic data on persons who received MAID.

Around 96% of receivers identified as caucasian, who comprise over 70% of Canada’s population. It’s unknown what produced the difference.

The second-highest reported ethnic group was East Asians (1.8%), who comprise approximately 5.7% of Canadians.

MAID remained the most commonly used method in Quebec, accounting for roughly 37% of all euthanasia fatalities despite the province’s population being only 22% of Canada.

The Quebec government initiated a study earlier this year to investigate why its euthanasia rate was so high.

Expanded Access to MAID

In 2021, the Trudeau government expanded access to MAID for persons who do not have a terminal diagnosis but wish to terminate their lives due to a chronic, disabling ailment. Earlier this year, it was announced that access to those with mental problems would be expanded again.

However, it was postponed for the second time because Canadian provinces, which control healthcare delivery, raised concerns about the system’s ability to handle such a large expansion.

On Wednesday, Health Canada defended the procedure, citing the criminal code’s “strict eligibility” conditions.

However, Cardus, a Christian research tank, claimed the latest MAID data were “alarming” and revealed that Canada has one of the world’s fastest-growing euthanasia regimes.

A report released in October by the Ontario government offered some insight on contentious cases in which people were awarded assisted dying when they were not reaching the end of their natural lives.

One example was a woman in her fifties with a history of melancholy and suicide ideation who was extremely sensitive to chemicals.

Her plea for euthanasia was granted after she was unable to find a home that could meet her medical requirements.

Another example made headlines recently, involving a Nova Scotia cancer patient who claimed she was twice asked if she was aware of assisted dying as an option while undergoing mastectomy surgery.

According to the National Post, the question “came up in completely inappropriate places”.

Many other Canadian news sites have also covered incidents in which people with disabilities considered assisted suicide owing to a lack of housing or disability assistance.

Related News:

BC Supreme Court Stops MAID Death of Woman from Alberta

(VOR News) – Individuals with diabetes utilising GLP-1 medications, such as Ozempic or Mounjaro, may be gaining an additional benefit, as suggested by recent research findings. This advantage is a diminished probability of developing a potentially fatal blood clot.

The study’s findings revealed that diabetic patients on specific medications exhibited a twenty percent reduced risk of developing venous thromboembolism (VTE) compared to those on alternative diabetic treatments.

Dr. Rushad Patell, the principal author of the study, remarked that “from a public health perspective, considering the widespread use of these [GLP-1] drugs, there exists potential to ascertain whether the overall incidence of VTE could be diminished at a national or population level as a consequence of this study.”

This pertains to the prevalence of diabetes medications.

Given the escalating risk of venous thromboembolism (VTE), it is plausible that this will result in a shift of the curve in the contrary direction.

At the American Society of Haematology’s (ASH) annual meeting, which took place in San Diego on Sunday, his team gave a presentation of their research findings. The meeting took place in San Diego.

It is essential to keep these data in a preliminary form until they are published in a peer-reviewed publication because they were presented at a diabetes medical congress. At the convention, the results were presented.

The researchers highlighted that vein thromboembolism (VTE) is a prevalent clot formation in veins that can pose significant risks. The two predominant forms of venous thromboembolism are pulmonary embolism and deep vein thrombosis (DVT). Pulmonary embolisms are defined by the migration of blood clots to the lungs, whereas deep vein thromboses (DVTs) are defined by the formation of blood clots in the legs.

Any form of venous thromboembolism (VTE) can lead to hospitalisation and potentially death if left untreated.

Could the newly discovered GLP-1 diabetic medications, which have achieved significant market success, aid in the prevention of venous thromboembolism?

Over 558,000 individuals in the United States were registered in a comprehensive health care database, and Patell’s team monitored the outcomes of these participants to gather information regarding the circumstances.

Patients were categorised into two groups, each including roughly 279,000 individuals: those utilising a GLP-1 drug for diabetes control and those receiving an older class of diabetes medication referred to as DPP4i. Patients with comparable health conditions were divided into these two groups. DPP4 inhibitors, conversely, do not induce weight loss in the manner that specific GLP-1 medications do.

In comparison to the cohort receiving alternative diabetes treatment, the group administered GLP-1 therapy exhibited an average incidence of venous thromboembolism (VTE) of 6.5 per 1,000 patients after one year.

Clots per 1,000 patients in the alternative diabetes cohort were 7.9.

According to Patell and his colleagues, the risk of blood clot formation was diminished by twenty percent as a result of this. The occurrence of pulmonary embolisms and deep vein thromboses (DVTs) has been shown to be decreasing.

The researchers found that the patient’s obesity status before taking GLP-1 did not affect the advantages regarding clotting risk, which were consistent regardless of the individual’s weight. The ambiguity remains over whether the decreased clotting risk associated with GLP-1s is due to weight loss in individuals or if an alternative mechanism is involved. There is insufficient comprehension concerning this issue.

“Further studies are necessary to ascertain the potential mechanism, whether via weight loss or alternative methods,” Patell stated in a news release disseminated at an ASH convention: “We must identify the potential mechanism through weight loss.”

The study could not establish that the use of GLP-1s was the cause of the reduction in clotting due to its retrospective design. The study was conducted, which was the reason for this situation. Consequently, Patell and his associates have asserted that a prospective clinical trial is essential to validate the evidence reported to date. Patell asserts that the newly acquired data may still offer direction to individuals with diabetes and the medical experts who manage their care.

His hypothesis is that this finding implies potential advantages in choosing a GLP-1 receptor agonist as an antidiabetic drug for patients. He stated, “It is crucial to consider thrombotic risk when selecting an antidiabetic agent for a patient.”

SOURCE: USN

SEE ALSO:

Vesta Care Dubai: Transforming Healthcare with Personalized Home Services

Bird Flu Testing Mandatory For Milk Supply In Exclusive-US Issued Order

As the healthcare industry in the United Arab Emirates (UAE) continues to grow, Vesta Care has emerged as a pioneer in redesigning patient care. More than just a healthcare company, Vesta Care portrays a life-changing energy, providing comprehensive and customized home services that bring better health directly to the population of Dubai.

Reshaping Home Healthcare

In contrast to the conventional model of healthcare techniques, Vesta Care interrupts the standard by offering its services directly to individuals’ homes throughout Dubai.

The wide suite of services covers Home Health Care, Physiotherapy, Nursing, and more, ensuring a comprehensive approach to better health within the familiar and comforting surroundings of one’s residence.

Personalized Home Health Solutions

At the core of Vesta Care’s mission lies a dedication to personalization. Recognizing each person’s unique healthcare requirements, Vesta Care’s services are tailored to various needs.

Home Nursing Services go beyond treatments, helping people maintain their privacy and dignity in the comfort of their homes.

Physiotherapy and Rehabilitation at Your Doorstep

Vesta Care’s commitment to holistic care includes physiotherapy and rehabilitation services delivered directly to your doorstep. More than just concentrating on treatment, Vesta Care fosters freedom and pride.

Home environments serve as supportive backgrounds, helping individuals actively engage in their recovery process. With individualized care plans designed according to each person’s unique demands, the qualified team fights to improve the overall quality of health.

Lab Tests at Home

Vesta Care reshapes the techniques used for lab tests to match the pace of modern technology in the UAE’s health industry. Lab at Home services offer more benefits than just convenience. They suggest a more private and personal link between a person and his health.

This prototype shift comprises a cultural development in healthcare awareness, focusing on personalized and accessible services. With up-to-date technology and a devoted team of professionals, Vesta Care provides accurate and timely results, taking the future of healthcare right to your doorstep.

Mother & Baby Care

Vesta Care provides specialized Mother and Baby Care services at home for mothers and newborns. They provide firm support and guidance from the early phases. Such personalized care exceeds clinical requirements, accentuating emotional well-being and guiding a smooth transition into parenthood.

An expert team of healthcare professionals is committed to creating a caring environment that gives new parents the information and confidence they need for a cheerful and healthy start to their parenthood journey. Vesta Care is committed to being a trusted partner in every step of this transformative experience.

Up-To-Date Healthcare Services

Vesta Care became a sign of novelty in the healthcare sector, seamlessly incorporating healthcare and technology. The company’s services are adjustable to modern needs – remote, mobile, available anytime, anywhere.

In a post-epidemic era, Vesta Care acknowledges the significance of prevention strategies and networks, securing a healthier future for its customers. With a modern approach, they constantly explore modern advancements to ensure that their healthcare services remain at the top of industry standards, offering their clients the best possible care.

Assisted Living & Rehabilitation Homes

Expanding its services, VestaCare embarked on Assisted Living & Rehabilitation Homes. These homes represent an understanding and caring environment for people requiring prolonged care. VestaCare’s strategy for Assisted Living exceeds medical attention; it is about making a home where individuals get care and thrive.

Comprehensive Healthcare Solutions

VestaCare’s dedication to being a healthcare partner for multiple needs is apparent in its range of services. From IV Infusion Therapy and hemodialysis at home to managed or occupational health services, tailored solutions for academic institutions, and much more. VestaCare rises as a one-stop destination for numerous healthcare issues.

Their commitment to quality surpasses individual services, fostering a holistic approach that covers varied healthcare challenges.

Vesta Care Global Standards and Qualified Solutions

With roots tracing back four decades, VestaCare draws on its wealth of experience and expertise. The company sticks to the most complicated global Clinical Governance principles, incorporating visions from its operational and therapeutic teams. The services are carefully planned using the international golden standards of CDC, WHO, and FDA, ensuring the maximum quality in healthcare delivery.

VestaCare exceeds the traditional boundaries of providing healthcare service; it is a life-changing partner in every individual’s health journey. By smoothly combining personalized care with advanced technology and a dedication to global standards, VestaCare is transforming healthcare in Dubai. In an era where health is foremost, VestaCare is a trustworthy companion, bringing healthcare home and reshaping lives.